New blocking agent against the development of LSD-25 psychosis.
D002317:Cardiovascular Agents; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004876:Ergot Alkaloids / Q000009:adverse effects*; D006801:Humans; D008238:Lysergic Acid Diethylamide; D001523:Mental Disorders; D011618:Psychotic Disorders
D002317:Cardiovascular Agents; D000697:Central Nervous System Stimulants; D004876:Ergot Alkaloids; D008238:Lysergic Acid Diethylamide
ANALEPTICS/effects; ERGOT ALKALOIDS/injurious effects; PSYCHOSES/experimental